Login to Your Account



GSK, J&J Join Index Ventures' Asset-Based $199M VC Fund

By Nuala Moran
Staff Writer

Wednesday, March 28, 2012
LONDON – Spring has arrived on cue for European biotech with the launch of a new €150 million (US$199 million) venture capital fund from Index Ventures – with backing and active involvement from two pharma partners, GlaxoSmithKline plc and Johnson & Johnson – to specialize in investing in early stage companies.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription